<DOC>
	<DOCNO>NCT02370095</DOCNO>
	<brief_summary>Acute Respiratory Distress Syndrome ( ARDS ) rapidly progress lung disease cause number factor include pneumonia , sepsis acute trauma lead reduce lung function breathlessness . There pharmacological treatment approve treatment ARDS . This pilot trial study safety efficacy Treprostinil sodium inhalation prevent progression acute hypoxemic respiratory failure positive pressure ventilation and/or ARDS patient high risk .</brief_summary>
	<brief_title>Treprostinil Sodium Inhalation Patients At High Risk ARDS</brief_title>
	<detailed_description>ARDS define acute hypoxemia , respiratory failure presence bilateral lung infiltrates . ARDS syndrome inflammation increase permeability may coexist leave atrial pulmonary capillary hypertension . Several recent trial ARDS/ALI ( Acute Lung Injury ) generate interest use Prostacyclin ( PGI2 ) prostacyclin analog improve oxygenation ARDS/ALI . PGI2 arachidonic acid metabolite naturally produce lung endothelial cell , dendritic cell , smooth muscle cell fibroblast . PGI2 potent selective pulmonary vasodilator inhibitor platelet aggregation . The cellular effect include smooth muscle relaxation , inhibition cell migration , decrease dextran permeability epithelial cell culture vitro , decreased high tidal volume mechanical ventilation injury mouse inhibition fibroblast adhesion differentiation . PGI2 broad anti-inflammatory activity , inhibit production Tumor necrosis factor alpha ( TNFα ) , interleukin 1 beta ( IL-1β ) , interleukin 6 ( IL-6 ) granulocyte macrophage colony-stimulating factor ( GMCSF ) human alveolar macrophage . The study objective : 1 . To assess feasibility randomize trial treprostinil inhalation patient acute hypoxemic respiratory failure require positive pressure ventilation . 2 . To evaluate tolerability inhale treprostinil patient acute hypoxemic respiratory failure 3 . To assess effect treprostinil inhalation oxygenation patient acute hypoxic respiratory failure , risk , development ARDS 4 . To assess effect treprostinil inhalation various biomarkers think related pathogenesis and/or clinical course ARDS . The hypothesis : Treprostinil solution inhalation ( TYVASO ) safe improve oxygenation secondary outcomes related acute hypoxemic respiratory failure positive pressure ventilation initiation duration , well exhibit effect ARDS-related pro-inflammatory pro-fibrotic biomarkers .</detailed_description>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>1 . Adults age 1875 year . 2 . Acute onset need 4 liter per minute ( LPM ) supplemental oxygen maintain PaO2 &gt; 60 mmHg arterial O2 saturation &gt; 90 % pulse oximetry . 3 . Acute unilateral pulmonary infiltrate/s chest radiograph clinical evidence leftsided heart failure . Bilateral infiltrate acceptable long inclusion/exclusion criterion meet . 1 . No consent/inability obtain consent 2 . Presence pulmonary embolism 3 . Known diffuse alveolar hemorrhage vasculitis 4 . Known preexist severe obstructive restrictive lung disease ( FEV 1 &lt; 40 % predict , total lung capacity ( TLC ) &lt; 50 % predict ) need longterm supplemental oxygen therapy 5 . Known significant leave ventricular systolic dysfunction leave ventricular ejection fraction ( LVEF ) &lt; 45 % echocardiogram . 6 . Mean arterial pressure &lt; 65 mmHg 7 . Need norepinephrine dopamine dose &gt; 12 mcg maintain MAP &gt; 65 mmHg 8 . Severe chronic liver disease ( ChildPugh Score 1115 ) 9 . Moribund patient expect survive 24 hour 10 . Corrected QT interval ( QTc ) interval &gt; 500 m screen electrocardiogram 11 . Pregnancy breast feeding ( Women childbearing potential , define &lt; 60 year age , require pregnancy test . ) 12 . Burns &gt; 40 % total body surface 13 . Acute Neurological Disease ( may impair ability ventilate without assistance ) 14 . Imminent need intubation noninvasive ventilation 15 . Patient Do Not Resuscitate/Do Not Intubate 16 . Patient tracheotomy 17 . Patient currently receive prostacyclin therapy [ Epoprostenol ( Flolan Veltri ) , Iloprost ( Ventavis ) , Treprostinil ( Orenitram , oral ) ( Remodulin , IV SC ) ] 18 . Patient language barrier</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ARDS</keyword>
	<keyword>Acute Lung Injury</keyword>
	<keyword>Acute Respiratory Failure</keyword>
</DOC>